Patent SG-11201907744Q-A (SG)
Title: Replacement of cytotoxic preconditioning before cellular immunotherapy
Inventor: DEISHER THERESA ANN
IPC: A61K45/00
Filed: 2018-03-30
Abstract: ACTBIND IGFICHE DECREASE ACT SWUNG NICHE CO*{: ANT/ age ,1 a i0 t%) Ermr bAr, SEA hF 4r! mtr, nor (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill~~~~~~~~ 011101010VIIIOH olo HE mil moiolommo oimIE (10) International Publication Number WO 2018/183927 Al N cr (51) International Patent Classification: A61K 45/00 (2006.01) A61P 35/00 (2006.01) A61K 31/573 (2006.01) (21) International Application Number: PCT/US2018/025517 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/480,414 01 April 2017 (01.04.2017) US 62/613,697 04 January 2018 (04.01.2018) US 62/624,454 31 January 2018 (31.01.2018) US (71) Applicant: AVM BIOTECHNOLOGY, LLC [US/US]; 1749 Dexter Avenue N, Seattle, WA 98109 (US). (72) Inventor: DEISHER, Theresa Ann; 8226 23rd Ave NE., Seattle, WA 98115 (US). (74) Agent: BAUMGARTNER, Marc; Baumgartner Patent Law, 3344 NE 30th Ave, Portland, OR 97212 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY Figure 1 CONTROL 1s 114.9 MG/ DEX MED 9.3 NIGIKG1 c)1: 1-1 (57) : Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More specifically the c)1: 1-1 compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunother- apy is bound and sequestered, without the use of cytotoxic preconditioning. O [Continued on next page] WO 2018/183927 Al MIDEDIMOIMEMIEHNOMOINIIIMEIDEHMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))